Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-19
DOI
10.1038/s41598-021-04618-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
- (2021) K.S. Tewari et al. ANNALS OF ONCOLOGY
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
- (2020) Andres Poveda et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
- (2020) Frank T. Zenke et al. MOLECULAR CANCER THERAPEUTICS
- Cervical cancer
- (2019) Paul A Cohen et al. LANCET
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
- (2019) Hannah C. Wise et al. Scientific Reports
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
- (2017) Krishnansu S Tewari et al. LANCET
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Human Papillomavirus and the DNA Damage Response: Exploiting Host Repair Pathways for Viral Replication
- (2017) Chelsey Spriggs et al. Viruses-Basel
- M3814, a DNA-dependent Protein Kinase Inhibitor (DNA-PKi), Potentiates the Effect of Ionizing Radiation (IR) in Xenotransplanted Tumors in Nude Mice
- (2016) L. Damstrup et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
- (2016) A Marijne Heeren et al. MODERN PATHOLOGY
- Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
- (2013) David Davidson et al. Frontiers in Pharmacology
- Inhibition of Homologous Recombination by DNA-Dependent Protein Kinase Requires Kinase Activity, Is Titratable, and Is Modulated by Autophosphorylation
- (2011) J. A. Neal et al. MOLECULAR AND CELLULAR BIOLOGY
- Choosing the right path: Does DNA-PK help make the decision?
- (2011) Jessica A. Neal et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Palliative radiotherapy for cervical carcinoma, a systematic review
- (2011) Luc van Lonkhuijzen et al. RADIOTHERAPY AND ONCOLOGY
- A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation
- (2010) Tracey A. Dobbs et al. DNA REPAIR
- Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery
- (2008) Cornelis J.A. Haasbeek et al. RADIOTHERAPY AND ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now